Indivior to merge with Supernus in stock-for-stock deal; Indivior stockholders to own 56.5% of combined company

Indivior Pharmaceuticals, Inc.

Exchange ratio: 1.5401 Indivior shares per Supernus share; Indivior stockholders own ~56.5%, Supernus ~43.5% on fully diluted basis.
Indivior to pay $1B special dividend pre-closing, funded in part by $650M senior secured term loan from Citibank.
Combined company renamed Supernus, Inc., trades on Nasdaq under 'SUPN'; Jack Khattar CEO, Timothy Dec CFO; board split 4-4.
Termination fees: Indivior pays $174M if it walks for superior proposal; Supernus pays $101M; closing subject to stockholder and regulatory approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.